Advanced Glycation End Products in Patients with Peripheral Arterial Occlusive Disease or Abdominal Aortic Aneurysm

Gepubliceerd: 14-08-2015 Laatst bijgewerkt: 15-05-2024

The primary objective is to compare the amount and types of AGEs of the arterial wall of both PAOD and AAA in patients with and without DM.

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON29072

Bron
Nationaal Trial Register

Verkorte titel
ARTERY

Aandoening

Patients with an abdominal aortic aneurysm (AAA) or peripheral arterial occlusive disease (PAOD) with and without diabetes mellitus.

Ondersteuning

Primaire sponsor: University Medical Center Groningen
Overige ondersteuning: University of Groningen

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Advanced glycation end products in the arterial wall

Toelichting onderzoek

Achtergrond van het onderzoek

Peripheral arterial occlusive disease (PAOD) and abdominal aortic aneurysms (AAA) are thought to have different pathophysiology. PAOD and AAA share smoking as major risk factor. However, DM is a common risk factor for occlusive vascular disease, but a protective factor for dilating disease. Accumulation of advanced glycation end products (AGEs) in the arterial wall could possibly explain the different effects of DM on these diseases. AGEs are sugar-modified moieties forming on proteins which are formed under influence of oxidative and glycemic stress. AGEs have the potential to create cross-links and to induce inflammatory and oxidative stress responses after binding to the receptor for AGE. Increased accumulation of AGEs is associated with increased risk of cardiovascular morbidity and mortality in several diseases, including PAOD.

Doel van het onderzoek

The primary objective is to compare the amount and types of AGEs of the arterial wall of both PAOD and AAA in patients with and without DM.

Onderzoeksopzet

Visit before surgery: vascular lab + laboratory for blood and urine.

Return 24h urine.

Surgery

Onderzoeksproduct en/of interventie

None

Contactpersonen

Publiek

Hanzeplein 1
J.D. Lefrandt
Groningen 9713 GZ
The Netherlands
+31 (0)50 361 2943

Wetenschappelijk

Hanzeplein 1
J.D. Lefrandt
Groningen 9713 GZ
The Netherlands
+31 (0)50 361 2943

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Age > 18 years old.

AAA or PAOD

Scheduled for open surgical repair of an AAA or bypass surgery or endarterectomy for PAOD.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Both AAA and PAOD

Inflammatory disease (rheumatoid artritis, SLE, giant cell artritis, Takayasu disease)

Inflammatory/mycotic aneurysm

Connective tissue disease (Marfans disease/ Ehlers-Danlos disease)

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	Niet-gerandomiseerd
Blindering:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-10-2015
Aantal proefpersonen:	120
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	14-08-2015
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 45188
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL5215
NTR-old	NTR5363
CCMO	NL45660.042.14
OMON	NL-OMON45188

Resultaten